Related Experiment Video
Updated: May 30, 2026
06:31
Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
Published on: October 6, 2023
2.1K
[Head-to-head trials in rheumatoid arthritis]
Diana Ernst1, Klaus Krüger2, Torsten Witte3
1Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Zeitschrift Fur Rheumatologie
|June 3, 2024
Summary
Head-to-head studies comparing disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) are crucial for treatment selection. While numerous studies exist, further research is needed to clarify drug-specific safety profiles, particularly for Janus kinase (JAK) inhibitors.
Area of Science:
- Rheumatology
- Pharmacology
- Clinical Trials
Context:
- Selecting optimal rheumatoid arthritis (RA) treatments requires robust comparative data.
- Multiple disease-modifying antirheumatic drugs (DMARDs) are available, necessitating efficacy and safety profile evaluations.
Purpose:
- To systematically review head-to-head studies comparing DMARDs in RA.
- To identify studies involving active comparator arms with at least one DMARD.
Summary:
- A review identified 23 studies comparing DMARDs in RA.
- Included comparisons involved Janus kinase (JAK) inhibitors versus methotrexate and adalimumab, alongside the oral surveillance study.
Impact:
- Highlights the substantial existing evidence base for DMARD comparisons in RA.
- Underscores the need for further head-to-head studies to resolve safety questions, such as the class effect of JAK inhibitors.
